Thanks to the recent advances in the techniques to detect tau biomarkers in vivo, the spreading pattern of tau within the brain can predict the resulting cognitive symptoms, and help clinicians and researchers understand that the majority of AD patients do not present with the stereotypic amnestic subtype. This evidence concerns the gene MAPT and Alzheimer disease.